Plasma p-tau217 Lumipulse Assay for Alzheimer Disease Diagnosis
(2025)Objective
To validate the Fujirebio Lumipulse automated p-tau217 assay for clinical AD diagnosis
Study Summary
• The Lumipulse automated plasma p-tau217 assay achieved AUC >0.95 for amyloid positivity across multiple cohorts, matching CSF biomarkers and approaching PET scan accuracy.
Intervention
Lumipulse G automated plasma p-tau217 assay (diagnostic validation study)
Inclusion Criteria
Memory clinic patients and research participants across the AD continuum from multiple international cohorts
Study Design
Arms: Array
Patients per Arm: Multi-cohort validation
Outcome
AUC >0.95 for amyloid positivity. Sensitivity >90%, specificity >85%. Performance maintained across age, sex, APOE subgroups. Runs on standard Lumipulse G1200 clinical lab equipment.
Bottom Line
The Lumipulse automated plasma p-tau217 assay achieved AUC >0.95 for amyloid positivity across multiple cohorts, matching CSF biomarkers and approaching PET scan accuracy.
Major Points
- Fujirebio Lumipulse G automated p-tau217 assay validated across multiple international cohorts.
- AUC >0.95 for detecting amyloid positivity — matching CSF biomarker performance.
- Sensitivity >90% and specificity >85% at optimized cutoffs.
- Performance maintained across age, sex, and APOE genotype subgroups.
- Runs on Lumipulse G1200 equipment already installed in thousands of clinical labs worldwide.
- Represents a pivotal step toward clinical deployment of AD blood testing in community settings.
Study Design
- Study Type
- Multi-cohort diagnostic accuracy study
- Randomization
- No
- Blinding
- N/A
- Follow-up
- Cross-sectional diagnostic study
Primary Outcome
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| - | >0.95 across cohorts | - | <0.001 |
Limitations & Criticisms
- Diagnostic thresholds may need local validation — cutoffs could vary by population and pre-analytical handling
- Performance in primary care settings (where testing would be most impactful) not yet validated
- Does not distinguish amyloid-positive from amyloid-positive-with-neurodegeneration (staging limited)
- Blood biomarker affected by renal clearance, BMI, and blood-brain barrier integrity
- Cost-effectiveness vs clinical assessment alone not yet demonstrated
Citation
Nat Med. 2025.